Biotech: Page 2
-
Whatās next for COVID dark horse Novavax?
Novavax scored a new COVID vaccine go-ahead for the 2023-24 season, but is it the boost the company needs?
By Kelly Bilodeau • Oct. 30, 2023 -
Q&A // Red Jacket winners 2023
Red Jacket: Helen Sabzevari, an immunotherapy pioneer
Precigen’s CEO is pushing for her next therapeutic breakthrough with innovative cell and gene therapy platforms.
By Meagan Parrish • Oct. 27, 2023 -
Explore the Trendlineā
Stock via Getty ImagesTrendlineWomen's health
As women’s health investments explode, major opportunities for growth remain.
By PharmaVoice staff -
Q&A // Red Jacket winners 2023
Red Jacket: Dr. Jeremy Levin, a transformational leader
A consummate life sciences executive who has led with boldness and devotion, Dr. Jeremy Levin considers himself a participant as well as a leader.
By Michael Gibney • Oct. 27, 2023 -
The 2023 Red Jacket honorees
This year's inductees to the PharmaVoice 100 "hall of fame" are leaders who have been at the forefront — and will stay at the forefront — of industry change.
By Meagan Parrish • Oct. 27, 2023 -
Biotech Spotlight
Cidaraās J&J-partnered immunotherapy could target flu and cancer
On a roll with promising data, the commercial-stage biotech is leveraging drug-Fc conjugates to aim a new weapon at viral targets.
By Alexandra Pecci • Oct. 26, 2023 -
Patient groups have become a powerhouse in R&D. Hereās a look at their impact.
“They have the money,” and they’re using it to influence drug development, according to the executive director of the IQVIA Institute for Human Data Science.
By Kelly Bilodeau • Oct. 25, 2023 -
Pfizerās new shot approval adds to a growing vaccine prowess
Pfizer brought in a new approval for a five-in-one shot for meningococcal disease, and the company has built a sizable vaccine business over time.
By Michael Gibney • Oct. 24, 2023 -
Biotech Spotlight
An āinverse vaccineā takes aim at autoimmune diseases
Backed by Pfizer, Anokion’s innovative approach to treating celiac, MS and more is showing early promise where others failed.
By Kelly Bilodeau • Oct. 23, 2023 -
From the rainforest to Wall Street ā Jaguar Healthās big play for revitalization
A pharma with a massive collection of rainforest-derived plants needs a regulatory win to overcome last year’s financial decline.
By Kelly Bilodeau • Oct. 17, 2023 -
The top biopharma conferences in 2024
A few key meetings remain this year, like ESMO and ASH, while next year’s events are already being planned. Here’s a list of conferences to keep in mind.
By Ned Pagliarulo • Oct. 16, 2023 -
PharmaVoice 100
PharmaVoice 100s: Rare disease warriors
Biopharma leaders pounding away at rare diseases so patients with few other options can have healthier lives.
By Michael Gibney • Oct. 16, 2023 -
Has the science of anti-aging caught up with the dream of a longer life?
Billionaire investors and a new crop of longevity biotechs are betting big money on a lifespan-altering tipping point.
By Kelly Bilodeau • Oct. 16, 2023 -
Opinion
Branded: The trademarks pharma leaders look up to
What do brands like Patagonia, Nike and Lego have to do with pharma? Here are some of the brands industry leaders relate to most — and how they inspire work in the life sciences.
By PharmaVoice Staff • Oct. 13, 2023 -
Deep Dive
A decade later, biotechās CRISPR revolution is still going strong
Once the specialty of a few select drugmakers, CRISPR gene editing is now an essential technology for a growing group of biotechs, many led by former students of the field's pioneering scientists.
By Gwendolyn Wu , Shaun Lucas , Julia Himmel • Oct. 12, 2023 -
Alnylam CEO, ādisappointedā with FDAās Onpattro rejection, pivots to the future
Yvonne Greenstreet, CEO of RNAi specialist Alnylam, addressed the surprise move by regulators and the company’s new future plans.
By Michael Gibney • Oct. 12, 2023 -
Q&A
5 minutes with ā IDEA Pharmaās Mike Rea
The CEO on the secrets of innovative pharma companies, his record collection and what he’d always rather be doing.
By Meagan Parrish • Oct. 11, 2023 -
Q&A // Biotech Spotlight
To close the pediatric innovation gap, this biotech has to think differently
Day One Biopharmaceuticals is bucking the cancer drug development trend by working with children and adults simultaneously.
By Alexandra Pecci • Oct. 11, 2023 -
Google bets on AI in the life sciences as ātechnology for a purposeā
A life sciences exec at Google Cloud talks about the future and fears for using AI in pharma.
By Alexandra Pecci • Oct. 10, 2023 -
Research in space yields clues about boosting bone health on Earth
A study aimed at helping astronauts decrease bone loss could open the door to novel osteoporosis meds.
By Kelly Bilodeau • Oct. 10, 2023 -
Biotech Spotlight
A biotech ātuningā the genome for a potentially safer gene therapy
Tune Therapeutics is hoping to overcome the pitfalls of CRISPR-style treatments with epigenetic editing.
By Kelly Bilodeau • Oct. 9, 2023 -
Key upcoming events for pharma execs
Trade shows and events focused on the industry’s hot-button topics, technologies and trends.
By Meagan Parrish • Oct. 6, 2023 -
FDAās āivory tower thinkingā ignores promising biomarkers, says a rare disease CEO
The FDA wouldn’t review a drug that was 90% effective. In rare diseases, this is too common, said Ultragenyx CEO Dr. Emil Kakkis and a leading rare disease researcher.
By Michael Gibney • Oct. 5, 2023 -
Where have all the unicorns gone? A look at 4 billion-dollar biotechs
Not every unicorn company lives up to its $1 billion promise. Here are four worth watching.
By Alexandra Pecci • Oct. 3, 2023 -
5 FDA decisions to watch in the fourth quarter
The regulator is considering approval of what would be the first CRISPR medicine, as well as important clearances for Alnylam, Bristol Myers, Amgen and Pfizer.
By Ned Pagliarulo , Jonathan Gardner • Oct. 2, 2023 -
The ALS therapy keeping the human pig heart transplant pumping
Eledon’s investigational ALS drug tegoprubart could also help prevent organ transplant rejections, the company says.
By Kelly Bilodeau • Oct. 2, 2023